Log in to search using one of your social media accounts:

 

Editorial: The Journal < b > < i > Chemotherapy < /i > < /b > Is for Cardio-Oncologists Too
Chemotherapy 2018;63:53 –54 (Source: Chemotherapy)
Source: Chemotherapy - February 9, 2018 Category: Cancer & Oncology Source Type: research

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study
Asymptomatic diastolic dysfunction (DD) with preserved left ventricular ejection fraction (LVEF) is suspected to precede late cardiac events in cancer survivors treated by chemotherapy. We conducted the first multicenter study of early DD induced by chemotherapy. Patients who were candidates for standard dose chemotherapy were screened for the absence of cardiovascular risk factors, LVEF ≥50%, normal-for-age diastolic function at echocardiography (E/A ratio, E wave deceleration time; DT), normal levels of potential DD biomarkers like Nt-proBNP (≤125 pg/mL), and cardiac troponin I (cTnI, ≤0.05 ng/mL). Mitral Dopple...
Source: Chemotherapy - February 9, 2018 Category: Cancer & Oncology Source Type: research

Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts
This study examined the antitumor efficacy of combination therapy consisting of S-1, LV, and oxaliplatin against 4 human gastric cancer xenografts: NUGC-4, St-40, SC-2, and SC-4.Methods: The antitumor efficacy was evaluated using human gastric cancer xenograft-bearing nude mice. S-1 and LV were administered orally once daily on days 1-7 at doses of 6.9 and 10 mg/kg, respectively. Oxaliplatin was administered intravenously at a dose of 8.3 mg/kg on day 1. The tumor volume was measured on day 15, and the relative tumor volume (RTV) was calculated.Results: In all 4 xenograft models, S-1 alone and oxaliplatin alone, but not LV...
Source: Chemotherapy - January 23, 2018 Category: Cancer & Oncology Source Type: research

Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model
This study is the first that reports the biochemical and histopathological evaluation of pazopanib-related hepatic toxicity.Chemotherapy 2018;63:39-45 (Source: Chemotherapy)
Source: Chemotherapy - January 23, 2018 Category: Cancer & Oncology Source Type: research

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy
We report on the potential value of a modified regimen that adopts a loading dose of CMS (bolus of 9 MU vs. conventional 3 MU every 8 h), followed by maintenance (3 MU every 8 h). Preliminary pharmacokinetic evidence for the feasibility and efficacy of this regimen is described for 2 patients.Chemotherapy 2018;63:35-38 (Source: Chemotherapy)
Source: Chemotherapy - December 21, 2017 Category: Cancer & Oncology Source Type: research

Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy
Conclusions: The authors propose a target teicoplanin Cmin of ≥15.2 mg/L for FN in patients with hematological malignancy.Chemotherapy 2018;63:29-34 (Source: Chemotherapy)
Source: Chemotherapy - November 23, 2017 Category: Cancer & Oncology Source Type: research

Antimicrobial Activity of Galangin and Its Effects on Murein Hydrolases of Vancomycin-Intermediate Staphylococcus aureus (VISA) Strain Mu50
This study aimed to investigate the antimicrobial activity of galangin againstS. aureus and its effects on the murein hydrolases of VISA strain Mu50. This is the first report on these effects of galangin, and it may help to improve the treatment for VISA infections by demonstrating the effective use of galangin.Methods: Firstly, the minimum inhibitory concentration (MIC) and growth curve were used to investigate the antimicrobial activity of galangin againstS. aureus. Secondly, transmission electron microscopy (TEM) was used to observe morphological changes of VISA strain Mu50. Thirdly, Triton X-100-induced autolysis and c...
Source: Chemotherapy - November 17, 2017 Category: Cancer & Oncology Source Type: research

Antimicrobial Activity of Galangin and Its Effects on Murein Hydrolases of Vancomycin-Intermediate < b > < i > Staphylococcus aureus < /i > < /b > (VISA) Strain Mu50
This study aimed to investigate the antimicrobial activity of galangin againstS. aureus and its effects on the murein hydrolases of VISA strain Mu50. This is the first report on these effects of galangin, and it may help to improve the treatment for VISA infections by demonstrating the effective use of galangin.Methods: Firstly, the minimum inhibitory concentration (MIC) and growth curve were used to investigate the antimicrobial activity of galangin againstS. aureus. Secondly, transmission electron microscopy (TEM) was used to observe morphological changes of VISA strain Mu50. Thirdly, Triton X-100-induced autolysis and c...
Source: Chemotherapy - November 16, 2017 Category: Cancer & Oncology Source Type: research

Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant < b > < i > Staphylococcus aureus < /i > < /b > Infection
Previous clinical studies have showed the clinical benefits of the initiation of treatment with a daptomycin (DAP) loading dose, but only a few studies have evaluated its antimicrobial benefits. We evaluated the efficacy of a DAP loading dose against methicillin-resistantStaphylococcus aureus (MRSA) infections in a neutropenic murine thigh infection model. Three MRSA isolates (DAP MIC: 0.5, 1, and 2 mg/L) were tested. Four DAP regimens simulating human concentration-time profiles, i.e., (i) day 1: 8 mg/kg and day 2: 6 mg/kg, (ii) days 1 and 2: 6 mg/kg/day, (iii) day 1: 8 mg/kg and day 2: 4 mg/kg, and (iv) days 1 and 2: 4 m...
Source: Chemotherapy - November 10, 2017 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Chemotherapy 2017;62:381 (Source: Chemotherapy)
Source: Chemotherapy - November 2, 2017 Category: Cancer & Oncology Source Type: research

Contents Vol. 62, 2017
Chemotherapy 2017;62:I-VI (Source: Chemotherapy)
Source: Chemotherapy - November 2, 2017 Category: Cancer & Oncology Source Type: research

Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer
Conclusions: Five-year overall and disease-free survival were not significantly different between the 2 groups. Large-scale prospective studies are necessary for the analysis of complications and survival rates.Chemotherapy 2018;63:8-12 (Source: Chemotherapy)
Source: Chemotherapy - November 1, 2017 Category: Cancer & Oncology Source Type: research

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy
Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was...
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing Klebsiella pneumoniae Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib
We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy. Given the loss of major molecular response, we switched treatment to dasatinib 100 mg daily, observing a reduction in BCR-ABL transcript, a significant improvement of anemia, and a gradual disappearance of fibrosis. After 7 years of dasatinib therapy the patient maintains a complete cytogenetic response and a deep molecular response; the last bone biopsy confirmed the absence of fibrosis.Chemotherapy 2017;62:350-352 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily sta...
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung
Background: Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung. We evaluated the effect of UFT on survival in maximum primary tumor diameter (T) categories as defined in the eighth edition of the TNM Classification (TNM8).Methods: Tumors were subgrouped on the basis of T category (TNM8) as follows: T1a, T ≤1 cm; T1b, 1 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Conclusions: Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.Chemotherapy 2017;62:361-366 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

α-Pinene Inhibits Human Prostate Cancer Growth in a Mouse Xenograft Model
Conclusions: These data strongly suggest that α-pinene inhibits prostate cancer growth in a xenograft model and may be an effective therapeutic agent for prostate cancer treatment.Chemotherapy 2018;63:1-7 (Source: Chemotherapy)
Source: Chemotherapy - October 25, 2017 Category: Cancer & Oncology Source Type: research

Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Conclusion: NSCLC patients treated with nivolumab as second-line therapy had a longer PFS compared to patients treated with docetaxel in a health care environment.Chemotherapy 2017;62:374-380 (Source: Chemotherapy)
Source: Chemotherapy - October 18, 2017 Category: Cancer & Oncology Source Type: research

Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature
We report the case of a young patient who experienced a drug-induced liver injury resulting in life-threatening acute liver failure after treatment with different antibiotics (amoxicillin, ciprofloxacin, cefazolin, clindamycin) and acetaminophen, or a combination of these drugs. Moreover, we provide an overview of the hepatotoxic potential of these drugs.Chemotherapy 2017;62:367-373 (Source: Chemotherapy)
Source: Chemotherapy - September 21, 2017 Category: Cancer & Oncology Source Type: research

Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Conclusions: Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.Chemotherapy 2017;62:361-366 (Source: Chemotherapy)
Source: Chemotherapy - August 25, 2017 Category: Cancer & Oncology Source Type: research

The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung
Background: Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung. We evaluated the effect of UFT on survival in maximum primary tumor diameter (T) categories as defined in the eighth edition of the TNM Classification (TNM8).Methods: Tumors were subgrouped on the basis of T category (TNM8) as follows: T1a, T ≤1 cm; T1b, 1 (Source: Chemotherapy)
Source: Chemotherapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic stem cell transplant. Eleven months after the transplant, she experienced molecular relapse. Mutational screening showed negativity for the T315I mutation, The patient underwent a salvage chemotherapy regimen with clofarabine + cyclophosphamide + steroids and ponatinib (clofarabine 70 mg i.v., days 1-5, cyclophosphamide 700 mg i.v., days 1-5, and ponatinib 45 mg p.o., daily sta...
Source: Chemotherapy - August 15, 2017 Category: Cancer & Oncology Source Type: research

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib
We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy. Given the loss of major molecular response, we switched treatment to dasatinib 100 mg daily, observing a reduction in BCR-ABL transcript, a significant improvement of anemia, and a gradual disappearance of fibrosis. After 7 years of dasatinib therapy the patient maintains a complete cytogenetic response and a deep molecular response; the last bone biopsy confirmed the absence of fibrosis.Chemotherapy 2017;62:350-352 (Source: Chemotherapy)
Source: Chemotherapy - July 25, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing Klebsiella pneumoniae Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 24, 2017 Category: Cancer & Oncology Source Type: research

Colistin Resistance in KPC-2- and SHV-5-Producing < b > < i > Klebsiella pneumoniae < /i > < /b > Clinical Isolates in Bulgaria
Conclusions: Although colistin use in Bulgaria only started moderately during 2014, the findings of the current study notify the appearance of colistin resistance among carbapenemase-producingKlebsiella species in another European region.Chemotherapy 2017;62:339-342 (Source: Chemotherapy)
Source: Chemotherapy - July 21, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research

Clinical Manifestations and Prognostic Factors of < b > < i > Pneumocystis jirovecii < /i > < /b > Pneumonia without HIV
Conclusion: We suggest that poor PS is an independent risk factor in non-HIV PCP, and a patient's PS and disease activity may correlate with outcome.Chemotherapy 2017;62:343-349 (Source: Chemotherapy)
Source: Chemotherapy - July 18, 2017 Category: Cancer & Oncology Source Type: research

High-Sensitivity Troponin T and NT-proBNP Kinetics in Breast Cancer Chemotherapy
Background/Aims: Doxorubicin (DOX) and trastuzumab (TRA) are associated with cardiac dysfunction.Method: High-sensitivity troponin T (hs-TnT) and brain natriuretic peptide attached to the amino acid N-terminal fragment in the prohormone (NT-proBNP) were measured before and on days +1, +2, +3, and +7 during cycles 1 and 2 of therapy with DOX or TRA in breast cancer patients.Results: Five of eleven DOX-treated women, compared with 2/11 TRA-treated women, had undetectable baseline hs-TnT. By day +1 of cycle 2, all the DOX-treated women (p = 0.03) but only 7/11 TRA-treated women (p = ns) had detectible hs-TnT. Time to peak was...
Source: Chemotherapy - July 13, 2017 Category: Cancer & Oncology Source Type: research

Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common < b > < i > DPYD < /i > < /b > Polymorphisms
While the majority of patients can be treated safely with fluoropyrimidine, some experience severe fluoropyrimidine-associated toxicity. The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene. Carriers of the rare allelic variantsDPYD*2A,DPYD*13, andDPYD D949V are more likely to experience severe adverse reactions during fluoropyrimidine-based therapy. However, these 3 genetic variants explain only a small percentage of the overall drug toxicity, and more frequent ones such as homozygous or comp...
Source: Chemotherapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid
Zoledronic acid is an established agent used in the management of metastatic bone disease. The administration of zoledronic acid improves overall survival (OS) of lung cancer patients with bone metastases receiving chemotherapy. However, it is currently unknown whether zoledronic acid-induced fever is associated with OS. The purpose of this study was to examine the association between zoledronic acid-induced fever and prognosis in lung cancer patients with bone metastases. We retrospectively analyzed 98 lung cancer patients with bone metastases who had received zoledronic acid. The end point outcome measure was OS. Multiva...
Source: Chemotherapy - June 12, 2017 Category: Cancer & Oncology Source Type: research

Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015
Conclusion: The combination of gemcitabine and vinorelbine is an effective and tolerable regimen for HER2-negative, taxane-pretreated, metastatic breast cancer patients in Japan.Chemotherapy 2017;62:307-313 (Source: Chemotherapy)
Source: Chemotherapy - June 12, 2017 Category: Cancer & Oncology Source Type: research

The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review
Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.Chemotherapy 2017;62:314-322 (Source: Chemotherapy)
Source: Chemotherapy - June 8, 2017 Category: Cancer & Oncology Source Type: research

Oxytetracycline Inhibits Mucus Secretion and Inflammation in Human Airway Epithelial Cells
In this study, the effects of oxytetracycline on mucus secretion and inflammation were examined by PCR and ELISA in the human airway epithelial cell line NCI-H292. Oxytetracycline (10 μg/mL) significantly inhibited TNF-α-induced MUC5AC gene expression and MUC5AC protein levels in NCI-H292 cells. It also downregulatedIL-8and IL-1 β gene expression and IL-1 β protein levels. Our findings demonstrated that oxytetracycline suppressed mucus production and inflammation in human respiratory epithelial cells, providing further evidence for the usefulness of oxytetracycline for human airway inflammatory diseases....
Source: Chemotherapy - June 2, 2017 Category: Cancer & Oncology Source Type: research

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion
We report a case of a 71-year-old man with colorectal cancer treated successfully with an oxaliplatin-based regimen who had disease relapse after 3 years. When treated again with oxaliplatin, he developed signs of an acute hypersensitivity reaction, and eventually had signs and symptoms consistent with DIC despite appropriate management. This case is unique in that a DIC reaction evolving from a hypersensitivity reaction occurred after the patient had already tolerated the drug years earlier. It suggests a possible immune-mediated etiology to this rare occurrence that should be kept in mind while utilizing this commonly em...
Source: Chemotherapy - May 15, 2017 Category: Cancer & Oncology Source Type: research

An Uncommon ST1224 NDM-1-Producing Klebsiella pneumoniae Isolated from the Bloodstream of a Leukemia Patient in China
Conclusion: The coexistence of various resistant genes is the mechanism for resistance to most antibiotics. Additionally, infections caused by multi-drug resistant bacteria increase the mortality of patients with immunodeficiency, which alerts clinicians to establish a rational and effective combination drug therapy.Chemotherapy 2017;62:262-268 (Source: Chemotherapy)
Source: Chemotherapy - May 11, 2017 Category: Cancer & Oncology Source Type: research

Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment
Conclusions: The use of hepatoprotective drugs may prevent liver injury in patients who are receiving anti-TB drugs without any significant AEs 4 weeks after the initiation of hepatoprotective medication.Chemotherapy 2017;62:269-278 (Source: Chemotherapy)
Source: Chemotherapy - May 11, 2017 Category: Cancer & Oncology Source Type: research

An Uncommon ST1224 NDM-1-Producing < b > < i > Klebsiella pneumoniae < /i > < /b > Isolated from the Bloodstream of a Leukemia Patient in China
Conclusion: The coexistence of various resistant genes is the mechanism for resistance to most antibiotics. Additionally, infections caused by multi-drug resistant bacteria increase the mortality of patients with immunodeficiency, which alerts clinicians to establish a rational and effective combination drug therapy.Chemotherapy 2017;62:262-268 (Source: Chemotherapy)
Source: Chemotherapy - May 10, 2017 Category: Cancer & Oncology Source Type: research

Duodenal Bulb Adenocarcinoma Benefitted from Neoadjuvant Chemotherapy: A Case Report
In this report, preoperative S-1 in combination with oxaliplatin neoadjuvant chemotherapy achieved a complete pathological response in the treatment of duodenal bulb adenocarcinoma. Neoadjuvant chemotherapy shows a better clinical efficacy in the treatment of duodenal bulb adenocarcinoma, but its value needs to be further verified.Chemotherapy 2017;62:290-294 (Source: Chemotherapy)
Source: Chemotherapy - May 10, 2017 Category: Cancer & Oncology Source Type: research

A Novel Approach of Synthesizing and Evaluating the Anticancer Potential of Silver Oxide Nanoparticles in vitro
Conclusions: AgONPs utilizing natural sources would be a new medicinal approach against a broad spectrum of malignancy.Chemotherapy 2017;62:279-289 (Source: Chemotherapy)
Source: Chemotherapy - May 10, 2017 Category: Cancer & Oncology Source Type: research

Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?
Conclusions: The use of hepatoprotective drugs may prevent liver injury in patients who are receiving anti-TB drugs without any significant AEs 4 weeks after the initiation of hepatoprotective medication.Chemotherapy 2017;62:269-278 (Source: Chemotherapy)
Source: Chemotherapy - May 10, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents
We retrospectively evaluated clinical data from patients with advanced non-small-cell lung cancer(NSCLC) treated with third-generation chemotherapy agents prior to treatment, to determine a reliable method for predicting prognosis in such patients. We analyzed 100 patients who received third-generation agents (paclitaxel, docetaxel, gemcitabine, irinotecan, and vinorelbine) for the treatment of advanced NSCLC. Factors significantly related to prognosis were evaluated using the Cox regression model, and the prognostic index (PI) was determined by combining these factors. The mean follow-up duration was 12.6 months (0.2-67.0...
Source: Chemotherapy - May 4, 2017 Category: Cancer & Oncology Source Type: research

Ten-Year Trends and Clinical Relevance of the Antimicrobial Resistance Genotype in Respiratory Isolates of < b > < i > Streptococcus pneumoniae < /i > < /b >
Conclusions: There was no difference in pathogenicity or clinical background between gPSSP, gPISP, and gPRSP. Antimicrobial resistance in respiratory isolates ofS. pneumoniae was more prevalent in genotypes than in phenotypes.Chemotherapy 2017;62:256-261 (Source: Chemotherapy)
Source: Chemotherapy - May 4, 2017 Category: Cancer & Oncology Source Type: research

Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase II α in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy
Conclusion: Our study demonstrated that CD4+ TILs and TOPOII α in pretreated cancer tissues were significantly correlated with CD8+ TILs. CD4+ TILs, CD8+ TILs, and TOPOIIα expression were predictors of pCR and 5-year DFS of TNBC patients who were treated with NAC, and TOPOIIα was an independent predictor of pCR. CD8+ TILs were a key factor in the predictio n of good 5-year OS rates of TNBC patients after taxane-anthracycline-based NAC.Chemotherapy 2017;62:246-255 (Source: Chemotherapy)
Source: Chemotherapy - May 4, 2017 Category: Cancer & Oncology Source Type: research

Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated Plasmodium falciparum Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia
Background: In severe malaria, intravenous artesunate may cause delayed haemolytic anaemia but there has been little evaluation of the propensity of oral artemisinin-based combination treatments (ACTs) to cause late-appearing anaemia.Methods: The frequency of anaemia (haematocrit (Source: Chemotherapy)
Source: Chemotherapy - April 28, 2017 Category: Cancer & Oncology Source Type: research

Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated < b > < i > Plasmodium falciparum < /i > < /b > Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia
Background: In severe malaria, intravenous artesunate may cause delayed haemolytic anaemia but there has been little evaluation of the propensity of oral artemisinin-based combination treatments (ACTs) to cause late-appearing anaemia.Methods: The frequency of anaemia (haematocrit (Source: Chemotherapy)
Source: Chemotherapy - April 27, 2017 Category: Cancer & Oncology Source Type: research